292 related articles for article (PubMed ID: 34760695)
1. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
Front Oncol; 2021; 11():733276. PubMed ID: 34760695
[TBL] [Abstract][Full Text] [Related]
2. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib in uncommon
Wang Y; Dorwal P; Rajadurai S; Arulananda S
Transl Lung Cancer Res; 2024 Feb; 13(2):434-442. PubMed ID: 38496692
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
6. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
Tatineni V; O'Shea PJ; Ozair A; Khosla AA; Saxena S; Rauf Y; Jia X; Murphy ES; Chao ST; Suh JH; Peereboom DM; Ahluwalia MS
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190312
[No Abstract] [Full Text] [Related]
7. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Le T; Gerber DE
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875928
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
[TBL] [Abstract][Full Text] [Related]
9. Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report.
Zhang Y; Shen JQ; Shao L; Chen Y; Lei L; Wang JL
World J Clin Cases; 2021 Sep; 9(27):8220-8225. PubMed ID: 34621884
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on Mobocertinib (TAK-788) in NSCLC with
Zhang SS; Zhu VW
Lung Cancer (Auckl); 2021; 12():61-65. PubMed ID: 34285620
[TBL] [Abstract][Full Text] [Related]
11. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
12. Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
Kelly WJ; Shah NJ; Subramaniam DS
Front Oncol; 2018; 8():208. PubMed ID: 30018881
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic
Zheng W; Niu N; Zeng J; Ke X; Jin S
Transl Cancer Res; 2022 Oct; 11(10):3895-3902. PubMed ID: 36388025
[TBL] [Abstract][Full Text] [Related]
15. Rechallenge of afatinib for
Araki T; Kanda S; Komatsu M; Sonehara K; Tateishi K; Takada M; Kato A; Yamamoto M; Nishie K; Hama M; Agatsuma T; Kakizaki Y; Yoshiike F; Matsuo A; Chiaki T; Samizo K; Takagi Y; Yamaura M; Hanaoka M; Koizumi T
Transl Lung Cancer Res; 2023 Jun; 12(6):1320-1327. PubMed ID: 37425417
[TBL] [Abstract][Full Text] [Related]
16. A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report.
Huang X; Yang Y; Wang P; Han-Zhang H; Ding L
Ann Palliat Med; 2021 Jun; 10(6):6997-7002. PubMed ID: 33183015
[TBL] [Abstract][Full Text] [Related]
17. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors.
Vasconcelos PENS; Gergis C; Viray H; Varkaris A; Fujii M; Rangachari D; VanderLaan PA; Kobayashi IS; Kobayashi SS; Costa DB
JTO Clin Res Rep; 2020 Sep; 1(3):. PubMed ID: 34104899
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?
Zhang SS; Ou SI
Lung Cancer (Auckl); 2022; 13():67-73. PubMed ID: 36317157
[TBL] [Abstract][Full Text] [Related]
19. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report.
Shen Q; Qu J; Chen Z; Zhou J
Front Oncol; 2021; 11():760097. PubMed ID: 34926262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
